Contact
 

 

The Canadian HIV Vaccine Initiative (CHVI) announced that the International Centre for Infectious Diseases (ICID) will house the new Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating...

The Lancet published a piece on correlates of protection and HIV vaccine development in its November issue.  Click below to read the article.

In the midst of the most promising era in HIV prevention research since the AIDS epidemic began, scientists from around the world will present more than 400 new studies outlining advances in the search for a safe and effective HIV vaccine at AIDS...

IAVI, The Scripps Research Institute, Theraclone Sciences and Monogram Biosciences (a LabCorp company), published in the journal, Nature, today the discovery of 17 new broadly neutralizing antibodies against HIV. Together these...

The HIV Vaccines and Microbicides Resource Tracking Working Group released its seventh report on HIV prevention research funding, which states that new investment is critical to capitalizing on HIV prevention breakthroughs. The full report is...

AVAC says results of new PrEP trials provide clear evidence that antiretroviral  drugs for prevention can help end the AIDS epidemic; calls for quick action  to move landmark HIV prevention results toward lifesaving programs.  Read...

IAVI today announced the appointment of Margaret (Margie) McGlynn as President and Chief Executive Officer. McGlynn, replaces Seth Berkley, IAVI’s Founding President and CEO.  The full announcement is below.

New Enterprise-OCTAVE Workshop for Young and Early Career Investigators

Statistical Methods in HIV Vaccine Trial Design and Evaluation

...

The Board of Directors of the Global HIV Vaccine Enterprise today announced that Alan Bernstein, Ph.D. will step down after three and a half years as the inaugural executive director of the Enterprise Secretariat at the end of June 2011.  ...

To commemorate the 30th anniversary of the first reported cases of what is now known as AIDS, Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, describes his personal experiences as a physician, leading HIV/AIDS...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account